iBio (IBIO) Stock Price, News & Analysis

Company Overview

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Key Stats

• Today's Range: $0.80 to $0.98
• 50-Day Range: $0.70 to $6.41
• 52-Week Range: $0.64 to $6.89
• Volume: 1.45 million shs
• Average Volume: 402,739 shs
• Market Capitalization: $8.39 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.30
• Consensus Rating: Buy

iBio Stock Analysis - MarketRank™

iBio scored higher than 36% of companies evaluated by MarketBeat, and ranked 698th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

iBio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

iBio has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for iBio are expected to decrease in the coming year, from ($1.74) to ($2.05) per share.

Price to Book Value per Share Ratio

iBio has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for IBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

iBio does not currently pay a dividend.

Dividend Growth

iBio does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for IBIO.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.27

News Sentiment

iBio has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for iBio this week, compared to 0 articles on an average week.

Search Interest

11 people have searched for IBIO on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.

MarketBeat Follows

1 people have added iBio to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, iBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.58% of the stock of iBio is held by insiders.

Percentage Held by Institutions

Only 7.90% of the stock of iBio is held by institutions.

IBIO Stock Analysis - Frequently Asked Questions

How have IBIO shares performed this year?

iBio's stock was trading at $2.45 at the start of the year. Since then, IBIO stock has decreased by 65.3% and is now trading at $0.85.
View the best growth stocks for 2025 here.

How were iBio's earnings last quarter?

iBio, Inc. (NYSE:IBIO) released its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.46) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.46).

Who are iBio's major shareholders?

Top institutional investors of iBio include Iridian Asset Management LLC CT (0.59%).
View institutional ownership trends.

How do I buy shares of iBio?

Shares of IBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some other companies that iBio investors own include Fastly (FSLY), Fortinet (FTNT), Snowflake (SNOW), Tesla (TSLA), Arbor Realty Trust (ABR) and Accenture (ACN).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 5/06/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:IBIO
• Previous Symbol: NYSE:IBIO
• CIK: 1420720
• Web: www.ibioinc.com
• Phone: 302-355-0650
• Fax: 302-356-1173
• Employees: 100
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.30
• High Stock Price Target: $5.00
• Low Stock Price Target: $3.60
• Potential Upside/Downside: +405.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,910,000.00
• Net Margins: N/A
• Pretax Margin: -3,795.73%
• Return on Equity: -73.15%
• Return on Assets: -45.51%

Debt

• Debt-to-Equity Ratio: 0.05
• Current Ratio: 1.76
• Quick Ratio: 1.76

Sales & Book Value

• Annual Sales: $375,000.00
• Price / Sales: 22.38
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.41 per share
• Price / Book: 0.60

Miscellaneous

• Outstanding Shares: 9,875,000
• Free Float: 9,818,000
• Market Cap: $8.39 million
• Optionable: N/A
• Beta: 1.19